The breadth of preclinical data strengthens Zymeworks' ADC platform narrative, which could attract partnership interest and re-rate the stock ahead of the ZW191 oral data readout. Traders should monitor for clinical validation of the pan-RASi payload strategy, especially in RAS-mutant cancers with high unmet need.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 17 $27.80entry
- T+1 · 7mo ago +0.18%α +0.37% · $27.85
- T+5 · 7mo ago +1.08%α +0.52% · $28.10
- T+20 · 6mo ago −13.81%α −19.18% · $23.96
- T+60 · 4mo ago −11.29%α −17.44% · $24.66
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks announced six preclinical poster presentations at AACR 2026 showcasing its next-generation antibody-drug conjugate (ADC) programs, including first-in-class pan-RAS inhibitor ADCs targeting solid tumors. New data highlight efficacy, tumor-selective delivery, and favorable tolerability across multiple programs. An oral presentation on Phase 1 data for ZW191 will follow on April 21.
Key Facts
- Six poster presentations at AACR 2026 feature preclinical data from Zymeworks' ADC and payload development programs.
- Programs include first-in-class pan-RAS inhibitor ADCs targeting Ly6E, CLDN18.2, PTK7, and FRα.
- ZW191 Phase 1 clinical data to be presented orally on April 21, 2026, from the first-in-human trial in advanced solid tumors.
- Preclinical data show strong anti-tumor activity at low doses (as low as 1 mg/kg), favorable tolerability, and potential for combination therapy.
- Novel eIF4A inhibitor payloads demonstrated robust anti-tumor activity across multiple targets, representing a new ADC payload class.
Financial Impact
Potential long-term value creation through pipeline expansion and platform validation; no immediate revenue impact.
Risk Factors
- Preclinical data may not translate to clinical efficacy.
- ZW191 Phase 1 data could show safety or tolerability concerns.
- Competition in the ADC and RAS inhibitor space is intensifying.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276454 |
Track record
25 reports on ZYME
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers